Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i1-2.70
pages 55-63

Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity

Licia Rivoltini
Istituto Nazionale dei Tumori, Milano, Italy
Douglas J. Loftus
laboratory of Cell Biology ,National Cancer Institute, NIH, Bethesda MD, USA
Paola Squarcina
Istituto Nazionale dei Tumori, Milano, Italy
Chiara Castelli
Istituto Nazionale dei Tumori, Milano, Italy
Francesca Rini
Istituto Nazionale dei Tumori, Milano, Italy
Flavio Arienti
Istituto Nazionale dei Tumori, Milano, Italy
Filiberto Belli
Istituto Nazionale dei Tumori, Milano, Italy
Francesco M. Marincola
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
Carsten Geisler
Institute of Medical Microbiology and Immunology, University of Copenhagen, Denmark
Alessandro Borsatti
lstituto "M. Negri", Milano, Italy
Ettore Appella
laboratory of Cell Biology ,National Cancer Institute, NIH, Bethesda MD, USA
Giorgio Parmiani
Istituto Nazionale dei Tumori, Milano, Italy

Краткое описание

Several T cell-recognized epitopes presented by melanoma cells have been identified recently. Despite the large array of epitopes potentially available for clinical use, it is still unclear which of these antigens could be effective in mediating anti-tumor responses when used as a vaccine. Preliminary studies showed that immunization of melanoma patients with epitopes derived from proteins of the MAGE family may result in significant clinical regressions. However, no sign of systemic immunization could be observed in peripheral blood of treated patients. Conversely, significant immunization (detected as increased antigen-specific CTL activity in peripheral blood) was obtained by vaccinating HLA-A2.1+ melanoma patients with the immunodominant epitope (residues 27-35) of the differentiation antigen MART-1, but this immunization was not accompanied by a significant clinical response. To implement immunotherapeuties capable of significantly impacting disease outcome, it is necessary to identify the potential mechanisms responsible for the failure of some antigens to mediate significant anti-tumor responses in vivo. In the case of the MART-127.35 epitope, we hypothesize that one of these mechanisms may be related to the existence of natural analogs of this peptide in other human normal proteins.

Ключевые слова: immunotherapy, peptides, antagonism.

Articles with similar content:

Application of Natural Killer T Cells in Antitumor Immunotherapy
Critical Reviews™ in Immunology, Vol.27, 2007, issue 6
Se-Ho Park, Changwan Hong
p53-Based Immunotherapy of Cancer
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Albert B. DeLeo
Roles of Smad3 in TGF-β Signaling During Carcinogenesis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.17, 2007, issue 4
Caroline Millet, Ying E. Zhang
Tumor Antigen Presentation by Dendritic Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 4
Nina Dickgreber, Ian F. Hermans, Troels R. Petersen
Stable Water Clusters−Mediated Molecular Alterations in Human Melanoma Cell Lines
Forum on Immunopathological Diseases and Therapeutics, Vol.3, 2012, issue 3-4
Stavroula Baritaki, Benjamin Bonavida